May 2019
BrightEdge Takes Venture Capital Approach to Accelerating Cancer Treatment,” KJZZ News Radio (an NPR member station based in Phoenix)
Related Information
The quest to cure cancer might sound lofty, but plenty of researchers, scientists advocates and investors are chipping away it all the time. Now, the American Cancer Society is launching a new approach with BrightEdge, a philanthropic impact fund. It functions like a venture capital firm but with an altruistic goal: To find innovations in cancer treatment and invest in them so they can get to patients sooner. Bob Crutchfield, managing director of BrightEdge, joined The Show to talk about the venture and why the American Cancer Society wanted to go in this direction.
In a recent interview with KJZZ News Radio, the award-winning Phoenix affiliate of the National Public Radio Network, BrightEdge Managing Director Bob Crutchfield discussed the fund’s mission and the types of cancer-treatment innovations being considered as potential investments. During the in-studio appearance, Bob explained the genesis of the new philanthropic impact fund and the American Cancer Society’s rationale for adopting such a venture-capital approach. In introducing the segment, host Lauren Gilger described BrightEdge as functioning "like a venture capital firm but with an altruistic goal: To find innovations in cancer treatment and invest in them so they can get to patients sooner.” You can listen to the full six-minute interview, which originally aired May 20, 2019, via this link to KJZZ website: https://kjzz.org/content/952636/brightedge-takes-venture-capital-approach-accelerating-cancer-treatment